Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 15314544)

Published in J Immunother on August 17, 2004

Authors

Antoni Ribas1, John A Glaspy, Yohan Lee, Vivian B Dissette, Elisabeth Seja, Huong T Vu, N Simon Tchekmedyian, Denise Oseguera, Begonya Comin-Anduix, Jennifer A Wargo, Saral N Amarnani, William H McBride, James S Economou, Lisa H Butterfield

Author Affiliations

1: Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA.

Articles citing this

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62

Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81

Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72

CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med (2009) 1.28

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18

Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09

The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One (2010) 1.09

Cancer vaccines. BMJ (2015) 1.07

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01

Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol (2013) 0.90

Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer (2012) 0.87

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84

Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology (2012) 0.84

Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One (2013) 0.83

New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs (2010) 0.83

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med (2011) 0.82

Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res (2013) 0.82

Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother (2016) 0.78

Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma. J Immunother Cancer (2013) 0.78

CTLA-4 polymorphisms associate with breast cancer susceptibility in Asians: a meta-analysis. PeerJ (2017) 0.75

Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines. Cancer Immunol Immunother (2008) 0.75

Articles by these authors

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87

Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol (2003) 3.70

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63

Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38

Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res (2009) 3.01

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol (2010) 2.88

Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87

Animal models for medical countermeasures to radiation exposure. Radiat Res (2010) 2.83

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer (2004) 2.80

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol (2008) 2.60

HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med (2011) 2.54

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48

Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A (2003) 2.40

An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35

Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26

Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg (2013) 2.26

Incidental pancreatic cysts: do we really know what we are watching? Pancreatology (2010) 2.22

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 1.89

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83

Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79

Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78

Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg (2011) 1.78

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol (2009) 1.77

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71

Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov (2013) 1.68

851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery (2012) 1.68

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67

The biological effectiveness of antiproton irradiation. Radiother Oncol (2006) 1.66

Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Clin Drug Investig (2006) 1.64

T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61

Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2011) 1.60

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56

Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53

Longitudinally mapping the influence of sex and androgen signaling on the dynamics of human cortical maturation in adolescence. Proc Natl Acad Sci U S A (2010) 1.52

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52

The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51

Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res (2009) 1.49

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48

A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48

Metastatic tumors in the pancreas in the modern era. J Am Coll Surg (2010) 1.45

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol (2010) 1.45

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol (2014) 1.45

Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res (2006) 1.45

Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol (2004) 1.44

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42

National Institutes of Health funding in radiation oncology: a snapshot. Int J Radiat Oncol Biol Phys (2013) 1.42